High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
Abstract Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated by immune-related adverse events (ir...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-01-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12890-018-0592-x |
id |
doaj-b8580c1cc6084517befb5c9d12fab248 |
---|---|
record_format |
Article |
spelling |
doaj-b8580c1cc6084517befb5c9d12fab2482020-11-24T21:39:53ZengBMCBMC Pulmonary Medicine1471-24662018-01-011811710.1186/s12890-018-0592-xHigh incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature reviewN. Koyama0O. Iwase1E. Nakashima2K. Kishida3T. Kondo4Y. Watanabe5H. Takahashi6Y. Umebayashi7Y. Ogawa8H. Miura9Department of Clinical Oncology, Tokyo Medical University Hachioji Medical CenterDepartment of Hematology, Tokyo Medical University Hachioji Medical CenterDepartment of Thoracic Surgery, Tokyo Medical University Hachioji Medical CenterDepartment of Dermatology, Tokyo Medical University Hachioji Medical CenterDepartment of Otolaryngology-Head and Neck Surgery, Tokyo Medical University Hachioji Medical CenterDepartment of Clinical Oncology, Tokyo Medical University Hachioji Medical CenterDepartment of Thoracic Surgery, Tokyo Medical University Hachioji Medical CenterDepartment of Dermatology, Tokyo Medical University Hachioji Medical CenterDepartment of Otolaryngology-Head and Neck Surgery, Tokyo Medical University Hachioji Medical CenterDepartment of Thoracic Surgery, Tokyo Medical University Hachioji Medical CenterAbstract Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated by immune-related adverse events (irAEs), including pneumonitis. Case presentation We present a case series of four patients with malignant melanoma, non-small cell lung cancer, and hypopharyngeal carcinoma who demonstrated pneumonitis induced by nivolumab, and further review clinicopathological characteristics of these patients in comparison with those of previously reported patients with nivolumab-induced pneumonitis. In our series, 20% of patients who were treated with nivolumab developed pneumonitis, all of which occurred approximately 2 weeks after the initiation of nivolumab treatment. Prompt recognition of the nivolumab-induced pneumonitis allowed for successful resolution. Computed tomography scan images of the patients demonstrated predominantly cryptogenic organizing pneumonia patterns. All patients were males, who had been heavily treated with antitumor drugs prior to nivolumab. Conclusions Our case series showed that nivolumab had a high incidence of drug-induced pneumonitis with early onset, supporting the need for renewed attention to nivolumab-induced pneumonitis, particularly in patients with a history of heavy antitumor treatments.http://link.springer.com/article/10.1186/s12890-018-0592-xDrug-induced pneumonitisImmune checkpoint inhibitorNivolumabNon-small cell lung cancerMalignant melanomaHypopharyngeal carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
N. Koyama O. Iwase E. Nakashima K. Kishida T. Kondo Y. Watanabe H. Takahashi Y. Umebayashi Y. Ogawa H. Miura |
spellingShingle |
N. Koyama O. Iwase E. Nakashima K. Kishida T. Kondo Y. Watanabe H. Takahashi Y. Umebayashi Y. Ogawa H. Miura High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review BMC Pulmonary Medicine Drug-induced pneumonitis Immune checkpoint inhibitor Nivolumab Non-small cell lung cancer Malignant melanoma Hypopharyngeal carcinoma |
author_facet |
N. Koyama O. Iwase E. Nakashima K. Kishida T. Kondo Y. Watanabe H. Takahashi Y. Umebayashi Y. Ogawa H. Miura |
author_sort |
N. Koyama |
title |
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review |
title_short |
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review |
title_full |
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review |
title_fullStr |
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review |
title_full_unstemmed |
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review |
title_sort |
high incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review |
publisher |
BMC |
series |
BMC Pulmonary Medicine |
issn |
1471-2466 |
publishDate |
2018-01-01 |
description |
Abstract Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated by immune-related adverse events (irAEs), including pneumonitis. Case presentation We present a case series of four patients with malignant melanoma, non-small cell lung cancer, and hypopharyngeal carcinoma who demonstrated pneumonitis induced by nivolumab, and further review clinicopathological characteristics of these patients in comparison with those of previously reported patients with nivolumab-induced pneumonitis. In our series, 20% of patients who were treated with nivolumab developed pneumonitis, all of which occurred approximately 2 weeks after the initiation of nivolumab treatment. Prompt recognition of the nivolumab-induced pneumonitis allowed for successful resolution. Computed tomography scan images of the patients demonstrated predominantly cryptogenic organizing pneumonia patterns. All patients were males, who had been heavily treated with antitumor drugs prior to nivolumab. Conclusions Our case series showed that nivolumab had a high incidence of drug-induced pneumonitis with early onset, supporting the need for renewed attention to nivolumab-induced pneumonitis, particularly in patients with a history of heavy antitumor treatments. |
topic |
Drug-induced pneumonitis Immune checkpoint inhibitor Nivolumab Non-small cell lung cancer Malignant melanoma Hypopharyngeal carcinoma |
url |
http://link.springer.com/article/10.1186/s12890-018-0592-x |
work_keys_str_mv |
AT nkoyama highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview AT oiwase highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview AT enakashima highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview AT kkishida highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview AT tkondo highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview AT ywatanabe highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview AT htakahashi highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview AT yumebayashi highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview AT yogawa highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview AT hmiura highincidenceandearlyonsetofnivolumabinducedpneumonitisfourcasereportsandliteraturereview |
_version_ |
1725928677114380288 |